argenx NV ADR (ARGX)vsDamora Therapeutics, Inc. (DMRA)
ARGX
argenx NV ADR
$781.72
+0.73%
HEALTHCARE · Cap: $48.85B
DMRA
Damora Therapeutics, Inc.
$25.36
-1.17%
HEALTHCARE · Cap: $1.46B
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 61/100 (C+).
ARGX
Buy61
out of 100
Grade: C+
DMRA
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+60.4%
Fair Value
$2106.55
Current Price
$781.72
$1324.83 discount
Intrinsic value data unavailable for DMRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Strong operational efficiency at 27.4%
No standout strengths identified
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 165.3x book value
Earnings declined 31.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : DMRA
DMRA has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 40.0x leaves little room for execution misses.
Bear Case : DMRA
The primary concerns for DMRA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while DMRA is a value play — different risk/reward profiles.
DMRA carries more volatility with a beta of 1.60 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (61/100 vs 17/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Damora Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company is headquartered in Copenhagen, Denmark.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?